Impact of Serotherapy on Immune Reconstitution and Survival Outcomes After Stem Cell Transplantations in Children: Thymoglobulin Versus Alemtuzumab

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 3, 2015, Pages 473-482

  Willemsen, Laura ^a   Jol van der Zijde, Cornelia M ^a   Admiraal, Rick ^a,b,c   Putter, Hein ^a   Jansen Hoogendijk, Anja M ^a   Ostaijen ten Dam, Monique M ^a   Wijnen, Juul T ^a   van Kesteren, Charlotte ^b,c   Waaijer, Jacqueline L M ^a   Lankester, Arjan C ^a   Bredius, Robbert G M ^a   van Tol, Maarten J D ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Alemtuzumab; Antithymocyte globulin; Children; Hematopoietic stem cell transplantation; Immune reconstitution; Survival

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN; ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; CHIMERA; COHORT ANALYSIS; CONTROLLED STUDY; DONOR CHIMERISM; DRUG EXPOSURE; EFFECTOR CELL; ENGRAFTMENT; EPSTEIN BARR VIRUS INFECTION; EVENT FREE SURVIVAL; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN ADENOVIRUS INFECTION; HUMAN CELL; IMMUNOPROPHYLAXIS; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MONOCYTE; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; NEUTROPHIL; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REDUCED INTENSITY CONDITIONING; T LYMPHOCYTE SUBPOPULATION; VIRUS REACTIVATION; WHOLE BODY RADIATION; ALLOGRAFT; CONVALESCENCE; DISEASE FREE SURVIVAL; DRUG EFFECTS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MORTALITY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADOLESCENT; ADULT; ALLOGRAFTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 84922815129     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.11.674     Document Type: Article

References (39)

1. Copelan E.A. Hematopoietic stem-cell transplantation. NEngl J Med 2006, 354:1813-1826.
2. Wayne A.S., Baird K., Egeler R.M. Hematopoietic stem cell transplantation for leukemia. Pediatr Clin North Am 2010, 57:1-25.
3. Moore A.S., Shaw P.J., Hallahan A.R., et al. Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group. Med J Aust 2009, 1903:121-125.
4. Vossen J.M., Donker A.E., Heemskerk M.B., et al. Unrelated donor marrow transplantation in children: transplant policy and outcome in Leiden Paediatrics SCT-Centre. Bone Marrow Transplant 2010, 45:87-95.
5. Veys P., Wynn R.F., Ahn K.W., et al. Impact of immune modulation with invivo T cell depletion and myeloablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia. Blood 2012, 119:6155-6161.
6. Bosch M., Dhadda M., Hoegh-Petersen M., et al. Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy 2012, 14:1258-1275.
7. Hoegh-Petersen M., Amin M.A., Liu Y., et al. Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse. Bone Marrow Transplant 2013, 48:105-114.
8. Mohty M. Mechanisms of action of antithymocyte globulin: T cell depletion and beyond. Leukemia 2007, 21:1387-1394.
9. Na I.K., Wittenbecher F., Dziubianau M., et al. Rabbit antithymocyte globulin (Thymoglobulin(R)) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients. Haematologica 2013, 98:23-30.
10. Stauch D., Dernier A., Sarmiento M.E., et al. Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity. PLoS One 2009, 4:e4709.
11. Ayuk F., Diyachenko G., Zabelina T., et al. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:913-919.
12. Jol-van der Zijde C.M., Bredius R.G., Jansen-Hoogendijk A.M., et al. IgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GVHD. Bone Marrow Transplant 2012, 47:360-368.
13. Shah A.J., Kapoor N., Crooks G.M., et al. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants. Biol Blood Marrow Transplant 2007, 13:584-593.
14. Schmidt-Hieber M., Schwarck S., Stroux A., et al. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of invivo T cell depletion. Int J Hematol 2010, 91:877-885.
15. Bosch M., Khan F.M., Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol 2012, 19:324-335.
16. Soiffer R.J., Lerademacher J., Ho V., et al. Impact of immune modulation with anti-T cell antibodies on the outcome of reduced-intensity allogeneichematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
17. Juliusson G., Theorin N., Karlsson K., et al. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant 2006, 37:503-510.
18. Rebello P., Cwynarski K., Varughese M., et al. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001, 3:261-267.
19. Waller E.K., Langston A.A., Lonial S., et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2003, 9:460-471.
20. Myers G.D., Krance R.A., Weiss H., et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant 2005, 36:1001-1008.
21. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
22. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
23. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
24. Niesters H.G., van Esser J., Fries E., et al. Development of a real-time quantitative assay for detection of Epstein-Barr virus. JClin Microbiol 2000, 38:712-715.
25. Lugthart G., van Ostaijen-Ten Dam M.M., Jol-van der Zijde C.M., et al. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on thereconstituting T cell compartment long-term after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014, 20:655-661.
26. Kalpoe J.S., Kroes A.C., de Jong M.D., et al. Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition oftreatment criteria by analysis of correlation to antigen detection. JClin Microbiol 2004, 42:1498-1504.
27. Claas E.C., Schilham M.W., de Brouwer C.S., et al. Internally controlled real-time PCR monitoring of adenovirus DNA load in serum or plasma of transplant recipients. JClin Microbiol 2005, 43:1738-1744.
28. Lankester A.C., Bierings M.B., van Wering E.R., et al. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia 2010, 24:1462-1469.
29. Duval M., Pedron B., Rohrlich P., et al. Immune reconstitution after haematopoietic transplantation with two different doses of pre-graft antithymocyte globulin. Bone Marrow Transplant 2002, 30:421-426.
30. Lindemans C.A., Chiesa R., Amrolia P.J., et al. Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. Blood 2014, 123:126-132.
31. Chawla S., Dharmani-Khan P., Liu Y., et al. High serum level of antithymocyte globulin immediately before graft infusion is associated with alow likelihood of chronic, but not acute, graft-versus-host disease. Biol Blood Marrow Transplant 2014, 20:1156-1162.
32. Jamieson A.M., Isnard P., Dorfman J.R., et al. Turnover and proliferation ofNK cells in steady state and lymphopenic conditions. JImmunol 2004, 172:864-870.
33. Dalle J.H., Dardari R., Menezes J., et al. Binding of thymoglobulin to naturalkiller cells leads to cell activation and interferon-gamma production. Transplantation 2009, 87:473-481.
34. Gartner F., Hieke S., Finke J., Bertz H. Lowering the alemtuzumab dose inreduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery. Cytotherapy 2013, 15:1237-1244.
35. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 980:2942-2947.
36. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
37. Norlin A.C., Remberger M. Acomparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2011, 86:57-66.
38. Cohen J., Gandhi M., Naik P., et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005, 129:229-239.
39. Jol-van der Zijde C.M., Bredius R.G., Jansen-Hoogendijk A.M., et al. Antibodies to anti-thymocyte globulin in aplastic anemia patients have a negative impact on hematopoietic SCT. Bone Marrow Transplant 2012, 47:1256-1258.